Ferring acquires LYSTEDA™ from Xanodyne Pharmaceuticals, Inc.
inFerring Pharmaceuticals today announced an agreement that will expand its Women’s Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical’s LYSTEDA™…